Pulse Biosciences (PLSE) updates investor deck with 2026 clinical goals
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Pulse Biosciences, Inc. furnished an updated investor presentation on its website, highlighting progress and plans across its cardiac and soft tissue programs. The deck adds new details on the pivotal clinical study of its nsPFA Cardiac Catheter for treating atrial fibrillation, describes the next-generation nPulse cardiac catheter under development, and outlines 2026 corporate goals in electrophysiology, cardiac surgery and soft tissue ablation. The company may use this presentation in meetings with investors and analysts. The investor deck is provided as an exhibit and is treated as furnished, not filed, under securities laws, and includes forward-looking statements subject to risks and uncertainties.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Terms
pivotal clinical study, nsPFA Cardiac Catheter, nPulse cardiac catheter, forward looking statements, +1 more
5 terms
pivotal clinical study medical
"new details about the Company’s pivotal clinical study of its nsPFA Cardiac Catheter"
A pivotal clinical study is the key, late-stage medical trial designed to show whether a drug or medical device works and is safe enough for regulators to approve it. Think of it as the final exam for a treatment: a strong pass typically clears the path to market access, while a failure can stop approval and materially affect expected sales, company value, and investor returns.
nsPFA Cardiac Catheter medical
"pivotal clinical study of its nsPFA Cardiac Catheter to treat atrial fibrillation"
nPulse cardiac catheter medical
"a description of the Company’s next generation nPulse cardiac catheter under development"
forward looking statements regulatory
"it contains forward looking statements that are subject to risks and uncertainties"
Statements about a company’s expected future performance, plans, goals, or projections that are not historical facts and involve assumptions and estimates. Investors care because these are predictions that guide decisions but can be wrong; like a weather forecast, they help set expectations and risk — if circumstances change, actual results may differ significantly, so investors should weigh them alongside hard data and risk factors.
electrophysiology medical
"the Company’s 2026 corporate goals in electrophysiology, cardiac surgery and soft tissue ablation"
The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April 16, 2026
|
|
||
|
(Exact Name of Registrant as Specified in Its Charter)
|
||
|
|
|
|
|
(State or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
|
||
|
|
||
|
(Address of Principal Executive Offices) (Zip Code)
|
||
|
|
||
|
(Registrant’s Telephone Number, Including Area Code)
|
||
|
Not Applicable
|
|
(Former Name or Former Address, If Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01
|
Regulation FD Disclosure.
|
On April 16, 2026, Pulse Biosciences, Inc., a Delaware corporation (the “Company”), posted an updated investor presentation on its website. The updated investor presentation (the “Investor Deck”) discloses, among other things, new details about the Company’s pivotal clinical study of its nsPFA Cardiac Catheter to treat atrial fibrillation, a description of the Company’s next generation nPulse cardiac catheter under development, and a summary of the Company’s 2026 corporate goals in electrophysiology, cardiac surgery and soft tissue ablation. The Company expects to use this updated investor presentation, either in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. A copy of the Investor Deck is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. The Investor Deck is also available on the Company’s website at www.pulsebiosciences.com under “Investors.”
Except for the Investor Deck, information contained on, or accessible through, the Company’s website is not a part of, and is not incorporated by reference in, this Current Report on Form 8-K. The information contained in the Investor Deck itself is summary information only and it contains forward looking statements that are subject to risks and uncertainties, including those set forth in the Company’s filings with the U.S. Securities and Exchange Commission. Also, the information in the Investor Deck is as of April 2026, and the Company undertakes no obligation to publicly update or revise the information contained in the Investor Deck or this Item 7.01, except as required by law, although it made do so from time to time.
The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly stated otherwise.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit
Number
|
Description
|
|
99.1
|
Investor Deck, dated April 16, 2026
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
PULSE BIOSCIENCES, INC.
|
|||
|
Date: April 16, 2026
|
By:
|
/s/ Jon Skinner
|
|
|
Jon Skinner
|
|||
|
Chief Financial Officer
(Principal Financial Officer) |
|||
Exhibit 99.1
FAQ
What did Pulse Biosciences (PLSE) disclose in this 8-K filing?
Pulse Biosciences furnished an updated investor presentation outlining its pivotal nsPFA Cardiac Catheter study, next-generation nPulse catheter development, and 2026 goals in electrophysiology, cardiac surgery and soft tissue ablation, for use in communications with investors and analysts.
Where can investors access the new Pulse Biosciences (PLSE) investor deck?
The updated investor deck is filed as Exhibit 99.1 and is available on Pulse Biosciences’ website at pulsebiosciences.com under the “Investors” section, providing summary information on clinical programs and 2026 corporate goals.
What clinical program details does Pulse Biosciences (PLSE) highlight in the investor deck?
The investor deck includes new details about Pulse Biosciences’ pivotal clinical study of its nsPFA Cardiac Catheter to treat atrial fibrillation, as well as information on its next-generation nPulse cardiac catheter currently under development.
How does Pulse Biosciences (PLSE) describe its 2026 corporate goals?
Pulse Biosciences summarizes 2026 corporate goals focused on three areas: electrophysiology, cardiac surgery and soft tissue ablation, giving investors a structured view of planned strategic priorities across its core technology platforms.
Are the Pulse Biosciences (PLSE) investor deck disclosures considered filed with the SEC?
The company states that Item 7.01 information and Exhibit 99.1 are furnished, not filed, under the Securities Exchange Act, limiting associated liability and incorporation by reference unless expressly stated otherwise in future filings.